Drakaki, Alexandra

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 2,199

Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer

Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 840

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 643

Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology

Pancreatic and Hepatic Oncology ResearchCancer-related Molecular Pathways

Cited by 110

Datopotamab deruxtecan in locally advanced/metastatic urothelial cancer: Preliminary results from the phase 1 TROPION-PanTumor01 study.

Lisberg, A., Drakaki, A., Meric-Bernstam, F., Alhalabi, O., Kojima, T., Kato, M., Spira, A. I., Salkeni, M. A., Heist, R., Gao, X., et al. (2024) · Journal of Clinical Oncology

Bladder and Urothelial Cancer TreatmentsLung Cancer Treatments and Mutations

Cited by 15

Next Generation T-Cell Therapy for Genitourinary Malignancies, Part A: Introduction and Current State of the Art

Pantuck, M., Palaskas, N., & Drakaki, A. (2018) · Cancer Treatment and Research Communications

Bladder and Urothelial Cancer TreatmentsNeuroendocrine Tumor Research Advances

Cited by 7